数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   BRVE
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

董事介绍

注：董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
David C. Lubner 男 Director 62 未披露 未持股 2026-06-30
Erez Chimovits 男 Director 62 未披露 未持股 2026-06-30
Travis Murdoch 男 Chief Executive Officer and Director and President 42 27.28万美元 825.03 2026-06-30
Jasper Bos 男 Director 51 未披露 未持股 2026-06-30
Jason Coloma 男 Director 50 1.10万美元 110.05 2026-06-30
Vineeta Agarwala 女 Director 39 未披露 未持股 2026-06-30
Travis Murdoch 男 Chief Executive Officer and Director and President 41 未披露 未持股 2026-06-30
David Malek 男 Director 48 未披露 未持股 2026-06-30
Tim Lohoff 男 Director 35 未披露 未持股 2026-06-30
Jason Coloma 男 Director 50 未披露 未持股 2026-06-30
Christopher Viehbacher 男 Chairman of the Board and Director 66 3.38万美元 67.65 2026-06-30
David Malek 男 Director 48 5.17万美元 100.91 2026-06-30

高管介绍

注：高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Travis Murdoch 男 Chief Executive Officer and Director and President 41 27.28万美元 825.03 2026-06-30
Travis Murdoch 男 Chief Executive Officer and Director and President 41 未披露 未持股 2026-06-30
J. Paul Rickey 男 Chief Financial Officer 47 137.57万美元 67.58 2026-06-30
Emil deGoma 男 Chief Medical Officer 50 未披露 未持股 2026-06-30
Michele Anderson 女 Chief Development Officer 59 14.39万美元 33.11 2026-06-30
Marc Evanchik 男 Chief Scientific Officer 53 未披露 未持股 2026-06-30
Tyler Chavez 男 Chief Business Officer 38 未披露 未持股 2026-06-30

董事简历

中英对照 |  中文 |  英文
David C. Lubner

David C. Lubner，他一直担任董事会成员（2020年7月以来）。从2016年1月到2020年6月，Lubner先生担任Ra Pharmaceuticals（一家生物技术公司，于2020年4月被UCB S.A.收购）的执行副总裁兼首席财务官。在此之前，Lubner先生曾担任Tetraphase Pharmaceuticals， Inc.（生物技术公司）的高级管理团队成员（从2006年成立到2016年1月），包括从2010年到2015年担任高级副总裁兼首席财务官。1999年至2005年，他担任PharMetrics公司（一家以患者为基础的药房和医疗索赔数据信息公司，于2015年被IMS Health收购）的首席财务官。1996年至1999年，他担任ProScript， Inc.（生物技术公司）的副总裁兼首席财务官。Lubner先生自2020年3月和2020年7月分别担任Dyne Therapeutics， Inc.（生物技术公司）和Therapeutics Acquisition Corp.（特殊目的收购公司）的董事会成员，此前曾担任Nightstar Therapeutics plc（基因治疗公司）的董事会成员，从2017年7月到2019年6月被Biogen Inc.收购。Lubner先生获得Northeastern大学工商管理学士学位和Bentley大学税务硕士学位。Lubner先生也是美国注册会计师协会的成员，也是Massachusetts的注册会计师。


David C. Lubner has served as a member of Braveheart Bio, Inc.'s board of directors since June 2026. Mr. Lubner currently serves as a Venture Partner at RA Ventures since October 2025. Mr. Lubner is also the Co Founder, President, Chief Operating Officer and member of the board of directors of Surmount LLC, an private early development life sciences company since August 2025. Previously, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., which was acquired by UCB S.A. in April 2020, from January 2016 until June 2020. Prior to Ra Pharmaceuticals, he served as Chief Financial Officer of several biotech companies including Chief Financial Officer of PharMetrics Inc., a healthcare informatics company from September 1999 until it was acquired by IQVIA (formerly IMS Health) in 2005. Mr. Lubner has served on the board of directors of Crescent Biopharma (Nasdaq: CBIO) since April 2025 and Dyne Therapeutics (Nasdaq: DYN) since March 2020 and currently serves as a member of the board of directors at several private biotechnology companies. He previously served on the board of directors of Arcellx, Inc. (Nasdaq: ACLX) from August 2020 until its acquisition by Gilead Sciences, Inc. in April 2026, POINT Biopharma (Nasdaq: PNT) from June 2021 until its acquisition by Eli Lilly & Co. in December 2023, CARGO Therapeutics (Nasdaq: CRGX) from July 2023 to August 2025, Vor Biopharma (Nasdaq: VOR) from July 2020 to August 2025, Gemini Therapeutics (Nasdaq: GMTX) from April 2020 to December 2022, and Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a blank check company focused on the healthcare industry from May 2020 to June 2021. Mr. Lubner is a former Certified Public Accountant and received a B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.
David C. Lubner，他一直担任董事会成员（2020年7月以来）。从2016年1月到2020年6月，Lubner先生担任Ra Pharmaceuticals（一家生物技术公司，于2020年4月被UCB S.A.收购）的执行副总裁兼首席财务官。在此之前，Lubner先生曾担任Tetraphase Pharmaceuticals， Inc.（生物技术公司）的高级管理团队成员（从2006年成立到2016年1月），包括从2010年到2015年担任高级副总裁兼首席财务官。1999年至2005年，他担任PharMetrics公司（一家以患者为基础的药房和医疗索赔数据信息公司，于2015年被IMS Health收购）的首席财务官。1996年至1999年，他担任ProScript， Inc.（生物技术公司）的副总裁兼首席财务官。Lubner先生自2020年3月和2020年7月分别担任Dyne Therapeutics， Inc.（生物技术公司）和Therapeutics Acquisition Corp.（特殊目的收购公司）的董事会成员，此前曾担任Nightstar Therapeutics plc（基因治疗公司）的董事会成员，从2017年7月到2019年6月被Biogen Inc.收购。Lubner先生获得Northeastern大学工商管理学士学位和Bentley大学税务硕士学位。Lubner先生也是美国注册会计师协会的成员，也是Massachusetts的注册会计师。
David C. Lubner has served as a member of Braveheart Bio, Inc.'s board of directors since June 2026. Mr. Lubner currently serves as a Venture Partner at RA Ventures since October 2025. Mr. Lubner is also the Co Founder, President, Chief Operating Officer and member of the board of directors of Surmount LLC, an private early development life sciences company since August 2025. Previously, Mr. Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals, Inc., which was acquired by UCB S.A. in April 2020, from January 2016 until June 2020. Prior to Ra Pharmaceuticals, he served as Chief Financial Officer of several biotech companies including Chief Financial Officer of PharMetrics Inc., a healthcare informatics company from September 1999 until it was acquired by IQVIA (formerly IMS Health) in 2005. Mr. Lubner has served on the board of directors of Crescent Biopharma (Nasdaq: CBIO) since April 2025 and Dyne Therapeutics (Nasdaq: DYN) since March 2020 and currently serves as a member of the board of directors at several private biotechnology companies. He previously served on the board of directors of Arcellx, Inc. (Nasdaq: ACLX) from August 2020 until its acquisition by Gilead Sciences, Inc. in April 2026, POINT Biopharma (Nasdaq: PNT) from June 2021 until its acquisition by Eli Lilly & Co. in December 2023, CARGO Therapeutics (Nasdaq: CRGX) from July 2023 to August 2025, Vor Biopharma (Nasdaq: VOR) from July 2020 to August 2025, Gemini Therapeutics (Nasdaq: GMTX) from April 2020 to December 2022, and Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a blank check company focused on the healthcare industry from May 2020 to June 2021. Mr. Lubner is a former Certified Public Accountant and received a B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.
Erez Chimovits

Erez Chimovits自2020年5月起担任Adarx Pharmaceuticals，Inc.董事会成员。Chimovits先生是投资公司OrbiMed的合伙人，自2010年11月以来，他在该公司担任过越来越多的职务。Chimovits先生目前在Upstream Bio，Inc.和几家私营公司的董事会任职。Chimovits先生此前曾在多家上市生物技术公司的董事会任职，包括从2016年1月至2021年3月的Adicet Bio公司、从2015年12月至2020年10月的BiomX公司、从2016年1月至2020年12月的LogicBio医疗，以及从2017年6月至2020年12月的Novus Therapeutics, Inc.，以及从2017年6月至2020年9月的TERM3，TERM3（现为Eledon Pharmaceuticals, Inc.）。在加入OrbiMed之前，Chimovits先生于2007年1月至2010年11月期间担任上市生物技术公司NasVax Ltd.（现为SciSparc Ltd.）的首席执行官。在此之前，Chimovits先生于2001年1月至2007年1月担任Compugen医疗美国公司总裁，该公司是一家上市生物技术公司Compugen Ltd.的子公司，并于1999年12月至2007年1月担任负责商业运营的执行副总裁。Chimovits先生在特拉维夫大学获得了微生物学学士学位、硕士学位和工商管理硕士学位。


Erez Chimovits has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since May 2020. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc.) from June 2017 until September 2020. Prior to joining OrbiMed, Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.), a public biotechnology company, from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., a public biotechnology company, from January 2001 to January 2007, and as Executive Vice President, Commercial Operations from December 1999 to January 2007. Mr. Chimovits earned his B.S., M.S. in Microbiology, and his M.B.A. from Tel Aviv University.
Erez Chimovits自2020年5月起担任Adarx Pharmaceuticals，Inc.董事会成员。Chimovits先生是投资公司OrbiMed的合伙人，自2010年11月以来，他在该公司担任过越来越多的职务。Chimovits先生目前在Upstream Bio，Inc.和几家私营公司的董事会任职。Chimovits先生此前曾在多家上市生物技术公司的董事会任职，包括从2016年1月至2021年3月的Adicet Bio公司、从2015年12月至2020年10月的BiomX公司、从2016年1月至2020年12月的LogicBio医疗，以及从2017年6月至2020年12月的Novus Therapeutics, Inc.，以及从2017年6月至2020年9月的TERM3，TERM3（现为Eledon Pharmaceuticals, Inc.）。在加入OrbiMed之前，Chimovits先生于2007年1月至2010年11月期间担任上市生物技术公司NasVax Ltd.（现为SciSparc Ltd.）的首席执行官。在此之前，Chimovits先生于2001年1月至2007年1月担任Compugen医疗美国公司总裁，该公司是一家上市生物技术公司Compugen Ltd.的子公司，并于1999年12月至2007年1月担任负责商业运营的执行副总裁。Chimovits先生在特拉维夫大学获得了微生物学学士学位、硕士学位和工商管理硕士学位。
Erez Chimovits has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since May 2020. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc.) from June 2017 until September 2020. Prior to joining OrbiMed, Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.), a public biotechnology company, from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., a public biotechnology company, from January 2001 to January 2007, and as Executive Vice President, Commercial Operations from December 1999 to January 2007. Mr. Chimovits earned his B.S., M.S. in Microbiology, and his M.B.A. from Tel Aviv University.
Travis Murdoch

Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。默多克博士自2022年8月起担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，从2020年9月至2022年10月，他在Zymergen，Inc.（现名：Ginkgo Bioworks Holdings Inc.（NYSE：DNA），在其合并后担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，默多克博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。由于拥有丰富的领导经验和生物制药行业知识，默多克有资格担任BraveHeart Bio，Inc.的董事会成员。


Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta. Murdoch is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive leadership experience and biopharmaceutical industry knowledge.
Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。默多克博士自2022年8月起担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，从2020年9月至2022年10月，他在Zymergen，Inc.（现名：Ginkgo Bioworks Holdings Inc.（NYSE：DNA），在其合并后担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，默多克博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。由于拥有丰富的领导经验和生物制药行业知识，默多克有资格担任BraveHeart Bio，Inc.的董事会成员。
Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta. Murdoch is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive leadership experience and biopharmaceutical industry knowledge.
Jasper Bos

Jasper Bos自2025年9月起担任BraveHeart Bio，Inc.董事会成员。BOS博士目前自2021年5月起担任投资于生物技术公司的全球风险投资公司Forbion Growth的普通合伙人，此前曾于2021年12月至2023年11月期间担任Forbion European收购公司（此前，纳斯达克：FRBN）的首席执行官。在加入Forbion位于Naarden的总部之前，Bos博士于2016年6月至2021年5月期间担任M Ventures的高级副总裁兼董事总经理，领导制药公司默克制药公司（纽约证券交易所代码：MRK）的风险投资部门。2009年5月至2016年5月，他在默沙东担任过各种职务，包括担任国家发言人默沙东荷兰，在那里他负责并联络默沙东在荷兰的所有活动。博斯博士目前担任多家私营公司的董事会成员。他此前曾于2023年11月至2025年7月在enGene Holdings，Inc.（纳斯达克：ENGN）董事会任职，并曾在多家私营生物技术公司的董事会任职。他在投资组合公司的多个运营角色中拥有经验，并在创建多个成功从默沙东分拆出来的公司方面发挥了关键作用，例如Prexton Therapeutics（出售给Lundbeck）和Calypso Biotech（出售给诺华）。Bos博士拥有荷兰格罗宁根大学药学博士学位。


Jasper Bos has served as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Dr. Bos is currently a General Partner at Forbion Growth, a global venture capital firm investing in biotech companies, since May 2021 and previously served as the Chief Executive Officer of Forbion European Acquisitions Corporation (previously, Nasdaq: FRBN) from December 2021 to November 2023. Before joining Forbion's Naarden based headquarters, Dr. Bos was Senior Vice President and Managing Director at M Ventures from June 2016 to May 2021, leading the venture capital arm of pharmaceutical company Merck & Co., Inc. (NYSE: MRK). He served in various roles at Merck from May 2009 to May 2016, including as Country Speaker Merck Netherlands where he assumed responsibility and liaised between all Merck activities in the Netherlands. Dr. Bos currently serves on the board of directors of several private companies. He has previously served on the board of directors of enGene Holdings, Inc. (Nasdaq: ENGN) from November 2023 to July 2025, and has served on multiple boards of directors of private biotech companies. He has experience in several operational roles in portfolio companies and played a key role in the creation of multiple successful spin out companies out of Merck, such as Prexton Therapeutics (sold to Lundbeck) and Calypso biotech (sold to Novartis). Dr. Bos holds a Ph.D. in Pharmacy from the University of Groningen, the Netherlands.
Jasper Bos自2025年9月起担任BraveHeart Bio，Inc.董事会成员。BOS博士目前自2021年5月起担任投资于生物技术公司的全球风险投资公司Forbion Growth的普通合伙人，此前曾于2021年12月至2023年11月期间担任Forbion European收购公司（此前，纳斯达克：FRBN）的首席执行官。在加入Forbion位于Naarden的总部之前，Bos博士于2016年6月至2021年5月期间担任M Ventures的高级副总裁兼董事总经理，领导制药公司默克制药公司（纽约证券交易所代码：MRK）的风险投资部门。2009年5月至2016年5月，他在默沙东担任过各种职务，包括担任国家发言人默沙东荷兰，在那里他负责并联络默沙东在荷兰的所有活动。博斯博士目前担任多家私营公司的董事会成员。他此前曾于2023年11月至2025年7月在enGene Holdings，Inc.（纳斯达克：ENGN）董事会任职，并曾在多家私营生物技术公司的董事会任职。他在投资组合公司的多个运营角色中拥有经验，并在创建多个成功从默沙东分拆出来的公司方面发挥了关键作用，例如Prexton Therapeutics（出售给Lundbeck）和Calypso Biotech（出售给诺华）。Bos博士拥有荷兰格罗宁根大学药学博士学位。
Jasper Bos has served as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Dr. Bos is currently a General Partner at Forbion Growth, a global venture capital firm investing in biotech companies, since May 2021 and previously served as the Chief Executive Officer of Forbion European Acquisitions Corporation (previously, Nasdaq: FRBN) from December 2021 to November 2023. Before joining Forbion's Naarden based headquarters, Dr. Bos was Senior Vice President and Managing Director at M Ventures from June 2016 to May 2021, leading the venture capital arm of pharmaceutical company Merck & Co., Inc. (NYSE: MRK). He served in various roles at Merck from May 2009 to May 2016, including as Country Speaker Merck Netherlands where he assumed responsibility and liaised between all Merck activities in the Netherlands. Dr. Bos currently serves on the board of directors of several private companies. He has previously served on the board of directors of enGene Holdings, Inc. (Nasdaq: ENGN) from November 2023 to July 2025, and has served on multiple boards of directors of private biotech companies. He has experience in several operational roles in portfolio companies and played a key role in the creation of multiple successful spin out companies out of Merck, such as Prexton Therapeutics (sold to Lundbeck) and Calypso biotech (sold to Novartis). Dr. Bos holds a Ph.D. in Pharmacy from the University of Groningen, the Netherlands.
Jason Coloma

自2024年5月成立以来，Jason Coloma一直担任BraveHeart Bio，Inc.的董事会成员。目前，Coloma博士自2019年6月起担任Maze Therapeutics，Inc.（纳斯达克：MAZE）的总裁、首席执行官和董事会成员。在此之前，他是Third Rock Ventures，LLC的风险合伙人，2016年7月至2019年6月。在加入Third Rock之前，Coloma博士于2016年7月至2017年7月期间担任Corvus Pharmaceuticals, Inc.（纳斯达克：CRVS）的高级副总裁兼首席商务官。在Third Rock任职期间，Coloma博士还曾于2018年8月至2019年8月在insitro，Inc.担任临时首席商务官，并于2017年7月至2018年11月在Celsius Therapeutics，Inc.（后被艾伯维公司（AbbVie Inc.，以下简称纳斯达克：ABBV））担任临时首席商务官。此前，他曾于2007年8月至2016年7月期间在罗氏集团和基因泰克（此前，NYSE：DNA）担任多个职务，包括副总裁兼肿瘤学合作领域全球治疗领域负责人以及研究技术合作领域全球负责人。他还曾于2002年6月至2005年7月在Cytokinetics公司（纳斯达克：CYTK）担任科学家，并曾在L.E.K. Consulting LLC和加州大学旧金山分校任职。Coloma博士此前曾于2021年4月至2024年8月在Bioage Labs，Inc.（纳斯达克：BIOA）担任董事会成员，目前在多家私营生物技术公司担任董事会成员。自2024年7月起，他还担任南加州大学和斯坦福大学的客座讲师。Coloma博士拥有旧金山大学生物学学士学位、加州大学伯克利分校的博士和硕士学位，以及达特茅斯学院塔克商学院的工商管理硕士学位。Coloma有资格担任BraveHeart Bio，Inc.的董事会成员，因为他在生物技术领域拥有丰富的高管经验。


Jason Coloma has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024. Currently, Dr. Coloma serves as President, Chief Executive Officer, and member of board of directors at Maze Therapeutics, Inc. (Nasdaq: MAZE) since June 2019. Prior to that, he was a venture partner at Third Rock Ventures, LLC, from July 2016 to June 2019. Before Third Rock, Dr. Coloma was SVP and Chief Business Officer at Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) from July 2016 to July 2017. While at Third Rock, Dr. Coloma also held the role of interim Chief Business Officer at insitro, Inc. from August 2018 to August 2019 and at Celsius Therapeutics, Inc. (later acquired by AbbVie Inc. (Nasdaq: ABBV)) from July 2017 to November 2018. Previously, he held several roles at Roche AG and Genentech, Inc. (previously, NYSE: DNA) between August 2007 and July 2016, including Vice President & Global Therapeutic Area Head of Oncology Partnering as well as Global Head of Research Technology Partnering. He also worked as a scientist at Cytokinetics Inc. (Nasdaq: CYTK) from June 2002 to July 2005 and held roles at L.E.K. Consulting LLC and University of California, San Francisco. Dr. Coloma previously served as a member of the board of directors at Bioage Labs, Inc. (Nasdaq: BIOA) from April 2021 to August 2024 and currently serves as a member of the board of directors at several private biotechnology companies. He is also a guest lecturer at University of Southern California and Stanford University since July 2024. Dr. Coloma holds a B.S. in Biology from the University of San Francisco, a Ph.D. and M.P.H. from the University of California, Berkeley, and an M.B.A. from the Tuck School of Business at Dartmouth College. Coloma is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive experience as an executive in the biotechnology sector.
自2024年5月成立以来，Jason Coloma一直担任BraveHeart Bio，Inc.的董事会成员。目前，Coloma博士自2019年6月起担任Maze Therapeutics，Inc.（纳斯达克：MAZE）的总裁、首席执行官和董事会成员。在此之前，他是Third Rock Ventures，LLC的风险合伙人，2016年7月至2019年6月。在加入Third Rock之前，Coloma博士于2016年7月至2017年7月期间担任Corvus Pharmaceuticals, Inc.（纳斯达克：CRVS）的高级副总裁兼首席商务官。在Third Rock任职期间，Coloma博士还曾于2018年8月至2019年8月在insitro，Inc.担任临时首席商务官，并于2017年7月至2018年11月在Celsius Therapeutics，Inc.（后被艾伯维公司（AbbVie Inc.，以下简称纳斯达克：ABBV））担任临时首席商务官。此前，他曾于2007年8月至2016年7月期间在罗氏集团和基因泰克（此前，NYSE：DNA）担任多个职务，包括副总裁兼肿瘤学合作领域全球治疗领域负责人以及研究技术合作领域全球负责人。他还曾于2002年6月至2005年7月在Cytokinetics公司（纳斯达克：CYTK）担任科学家，并曾在L.E.K. Consulting LLC和加州大学旧金山分校任职。Coloma博士此前曾于2021年4月至2024年8月在Bioage Labs，Inc.（纳斯达克：BIOA）担任董事会成员，目前在多家私营生物技术公司担任董事会成员。自2024年7月起，他还担任南加州大学和斯坦福大学的客座讲师。Coloma博士拥有旧金山大学生物学学士学位、加州大学伯克利分校的博士和硕士学位，以及达特茅斯学院塔克商学院的工商管理硕士学位。Coloma有资格担任BraveHeart Bio，Inc.的董事会成员，因为他在生物技术领域拥有丰富的高管经验。
Jason Coloma has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024. Currently, Dr. Coloma serves as President, Chief Executive Officer, and member of board of directors at Maze Therapeutics, Inc. (Nasdaq: MAZE) since June 2019. Prior to that, he was a venture partner at Third Rock Ventures, LLC, from July 2016 to June 2019. Before Third Rock, Dr. Coloma was SVP and Chief Business Officer at Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) from July 2016 to July 2017. While at Third Rock, Dr. Coloma also held the role of interim Chief Business Officer at insitro, Inc. from August 2018 to August 2019 and at Celsius Therapeutics, Inc. (later acquired by AbbVie Inc. (Nasdaq: ABBV)) from July 2017 to November 2018. Previously, he held several roles at Roche AG and Genentech, Inc. (previously, NYSE: DNA) between August 2007 and July 2016, including Vice President & Global Therapeutic Area Head of Oncology Partnering as well as Global Head of Research Technology Partnering. He also worked as a scientist at Cytokinetics Inc. (Nasdaq: CYTK) from June 2002 to July 2005 and held roles at L.E.K. Consulting LLC and University of California, San Francisco. Dr. Coloma previously served as a member of the board of directors at Bioage Labs, Inc. (Nasdaq: BIOA) from April 2021 to August 2024 and currently serves as a member of the board of directors at several private biotechnology companies. He is also a guest lecturer at University of Southern California and Stanford University since July 2024. Dr. Coloma holds a B.S. in Biology from the University of San Francisco, a Ph.D. and M.P.H. from the University of California, Berkeley, and an M.B.A. from the Tuck School of Business at Dartmouth College. Coloma is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive experience as an executive in the biotechnology sector.
Vineeta Agarwala

Vineeta Agarwala将在本次发行结束后立即作为BraveHeart Bio，Inc.董事会成员加入。Agarwala博士自2020年1月起担任Andreessen Horowitz的普通合伙人，专注于生物技术和健康技术公司的投资，并在多家私营投资组合公司的董事会任职。在加入Andreessen Horowitz之前，Agarwala博士曾在2015年3月至2019年12月期间担任Google Ventures的风险合伙人，支持生物技术和数字健康领域的早期投资。2016年8月至2018年6月，Agarwala博士在Flatiron Health，Inc担任产品管理总监，在那里她帮助建立了一个肿瘤学数据平台，并领导了一项合作，以整合真实世界的临床和基因组数据集。Agarwala博士自2024年1月起担任泰尼特保健公司（NYSE：THC）的董事会成员。她自2021年4月起担任美国国家风险投资协会（NVCA）董事会成员，并担任NVCA董事会主席，任期为2025-2026年。Agarwala博士是斯坦福大学医学院的兼职临床助理教授，自2020年起在该学院的初级保健和Population Health部门执业。Agarwala博士拥有斯坦福大学生物物理学学士学位、哈佛医学院通过哈佛麻省理工学院HST项目获得的医学博士学位，以及哈佛大学生物物理学博士学位，她在布罗德研究所进行的博士研究专注于人类疾病的遗传原因。她在斯坦福医院和诊所完成了内科住院医师实习。


Vineeta Agarwala shall join as a member of Braveheart Bio, Inc.'s board of directors immediately following the closing of this offering. Dr. Agarwala has served as a General Partner at Andreessen Horowitz since January 2020, where she focuses on investments in biotechnology and health technology companies and serves on the boards of directors of several private portfolio companies. Prior to joining Andreessen Horowitz, Dr. Agarwala served as a Venture Partner at Google Ventures, from March 2015 to December 2019, where she supported early stage investments across biotechnology and digital health. From August 2016 to June 2018, Dr. Agarwala served as Director of Product Management at Flatiron Health, Inc, where she helped build an oncology data platform and led a partnership to integrate real world clinical and genomic datasets. Dr. Agarwala has served on the board of directors of Tenet Healthcare Corporation (NYSE: THC) since January 2024. She has served as a member of the board of directors of the National Venture Capital Association (NVCA) since April 2021 and also served as Chair of the NVCA board of directors for the 2025 2026 term. Dr. Agarwala is an Adjunct Clinical Assistant Professor at Stanford University School of Medicine, where she practices in the Division of Primary Care and Population Health since 2020. Dr. Agarwala holds a B.S. in Biophysics from Stanford University, an M.D. from Harvard Medical School through the Harvard MIT HST Program, and a Ph.D. in Biophysics from Harvard University, where her doctoral research conducted at the Broad Institute focused on genetic causes of human disease. She completed her residency in internal medicine at Stanford Hospital & Clinics.
Vineeta Agarwala将在本次发行结束后立即作为BraveHeart Bio，Inc.董事会成员加入。Agarwala博士自2020年1月起担任Andreessen Horowitz的普通合伙人，专注于生物技术和健康技术公司的投资，并在多家私营投资组合公司的董事会任职。在加入Andreessen Horowitz之前，Agarwala博士曾在2015年3月至2019年12月期间担任Google Ventures的风险合伙人，支持生物技术和数字健康领域的早期投资。2016年8月至2018年6月，Agarwala博士在Flatiron Health，Inc担任产品管理总监，在那里她帮助建立了一个肿瘤学数据平台，并领导了一项合作，以整合真实世界的临床和基因组数据集。Agarwala博士自2024年1月起担任泰尼特保健公司（NYSE：THC）的董事会成员。她自2021年4月起担任美国国家风险投资协会（NVCA）董事会成员，并担任NVCA董事会主席，任期为2025-2026年。Agarwala博士是斯坦福大学医学院的兼职临床助理教授，自2020年起在该学院的初级保健和Population Health部门执业。Agarwala博士拥有斯坦福大学生物物理学学士学位、哈佛医学院通过哈佛麻省理工学院HST项目获得的医学博士学位，以及哈佛大学生物物理学博士学位，她在布罗德研究所进行的博士研究专注于人类疾病的遗传原因。她在斯坦福医院和诊所完成了内科住院医师实习。
Vineeta Agarwala shall join as a member of Braveheart Bio, Inc.'s board of directors immediately following the closing of this offering. Dr. Agarwala has served as a General Partner at Andreessen Horowitz since January 2020, where she focuses on investments in biotechnology and health technology companies and serves on the boards of directors of several private portfolio companies. Prior to joining Andreessen Horowitz, Dr. Agarwala served as a Venture Partner at Google Ventures, from March 2015 to December 2019, where she supported early stage investments across biotechnology and digital health. From August 2016 to June 2018, Dr. Agarwala served as Director of Product Management at Flatiron Health, Inc, where she helped build an oncology data platform and led a partnership to integrate real world clinical and genomic datasets. Dr. Agarwala has served on the board of directors of Tenet Healthcare Corporation (NYSE: THC) since January 2024. She has served as a member of the board of directors of the National Venture Capital Association (NVCA) since April 2021 and also served as Chair of the NVCA board of directors for the 2025 2026 term. Dr. Agarwala is an Adjunct Clinical Assistant Professor at Stanford University School of Medicine, where she practices in the Division of Primary Care and Population Health since 2020. Dr. Agarwala holds a B.S. in Biophysics from Stanford University, an M.D. from Harvard Medical School through the Harvard MIT HST Program, and a Ph.D. in Biophysics from Harvard University, where her doctoral research conducted at the Broad Institute focused on genetic causes of human disease. She completed her residency in internal medicine at Stanford Hospital & Clinics.
Travis Murdoch

Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月期间担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。自2022年8月起，默多克博士担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，2020年9月至2022年10月，他在Zymergen，Inc.（合并后现名为Ginkgo Bioworks Holdings Inc.（NYSE：DNA））担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，Murdoch博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。


Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta.
Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月期间担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。自2022年8月起，默多克博士担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，2020年9月至2022年10月，他在Zymergen，Inc.（合并后现名为Ginkgo Bioworks Holdings Inc.（NYSE：DNA））担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，Murdoch博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。
Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta.
David Malek

David Malek自2024年5月成立以来一直担任BraveHeart Bio，Inc.的董事会成员，此前曾于2024年5月至2025年10月期间担任BraveHeart Bio，Inc.的总裁。目前，Malek先生自2024年11月起担任一家早期发展生命科学公司的联合创始人和首席运营官。此前，他曾于2018年4月至2025年8月在Pivotal Life Sciences LLC担任多个职务，Pivotal Life Sciences LLC是一家生命科学风险投资公司，投资于以变革性治疗为重点的医疗保健公司，包括担任运营合伙人、投资总监和风险合伙人。在此之前，Malek先生于2017年4月至2021年12月担任OncXerna Therapeutics，Inc.的首席商务官。此前，他于2019年5月至2020年10月在Arctic Vision Ltd.担任首席商务官，并于2011年10月至2018年3月在BioLineRx Ltd.（纳斯达克：BLRX）担任首席商务官。他的职业生涯始于赛诺菲 S.A.（纳斯达克：SNY），于2007年6月至2011年9月期间担任过多个职务。Malek先生还曾担任多家私营生物技术公司的董事会成员。他拥有海法大学的学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。


David Malek has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024 and previously served as Braveheart Bio, Inc.'s President from May 2024 to October 2025. Currently, Mr. Malek is the Co Founder and Chief Operating Officer of an early development life sciences company since November 2024. Previously, he held various roles at Pivotal Life Sciences LLC, a life sciences venture capital firm investing in transformative therapeutic focused healthcare companies, from April 2018 to August 2025, including as Operating Partner, Investment Director and Venture Partner. Prior to that, Mr. Malek was the Chief Business Officer at OncXerna Therapeutics, Inc. from April 2017 to December 2021. Previously, he was the Chief Business Officer at Arctic Vision Ltd. from May 2019 to October 2020 and at BioLineRx Ltd. (Nasdaq: BLRX) from October 2011 to March 2018. He started his career at Sanofi S.A. (Nasdaq: SNY) where he held various roles from June 2007 to September 2011. Mr. Malek has also served as a member of the board of directors at several private biotechnology companies. He holds an B.A. from University of Haifa and an M.B.A. from the Tuck School of Business at Dartmouth College.
David Malek自2024年5月成立以来一直担任BraveHeart Bio，Inc.的董事会成员，此前曾于2024年5月至2025年10月期间担任BraveHeart Bio，Inc.的总裁。目前，Malek先生自2024年11月起担任一家早期发展生命科学公司的联合创始人和首席运营官。此前，他曾于2018年4月至2025年8月在Pivotal Life Sciences LLC担任多个职务，Pivotal Life Sciences LLC是一家生命科学风险投资公司，投资于以变革性治疗为重点的医疗保健公司，包括担任运营合伙人、投资总监和风险合伙人。在此之前，Malek先生于2017年4月至2021年12月担任OncXerna Therapeutics，Inc.的首席商务官。此前，他于2019年5月至2020年10月在Arctic Vision Ltd.担任首席商务官，并于2011年10月至2018年3月在BioLineRx Ltd.（纳斯达克：BLRX）担任首席商务官。他的职业生涯始于赛诺菲 S.A.（纳斯达克：SNY），于2007年6月至2011年9月期间担任过多个职务。Malek先生还曾担任多家私营生物技术公司的董事会成员。他拥有海法大学的学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
David Malek has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024 and previously served as Braveheart Bio, Inc.'s President from May 2024 to October 2025. Currently, Mr. Malek is the Co Founder and Chief Operating Officer of an early development life sciences company since November 2024. Previously, he held various roles at Pivotal Life Sciences LLC, a life sciences venture capital firm investing in transformative therapeutic focused healthcare companies, from April 2018 to August 2025, including as Operating Partner, Investment Director and Venture Partner. Prior to that, Mr. Malek was the Chief Business Officer at OncXerna Therapeutics, Inc. from April 2017 to December 2021. Previously, he was the Chief Business Officer at Arctic Vision Ltd. from May 2019 to October 2020 and at BioLineRx Ltd. (Nasdaq: BLRX) from October 2011 to March 2018. He started his career at Sanofi S.A. (Nasdaq: SNY) where he held various roles from June 2007 to September 2011. Mr. Malek has also served as a member of the board of directors at several private biotechnology companies. He holds an B.A. from University of Haifa and an M.B.A. from the Tuck School of Business at Dartmouth College.
Tim Lohoff

Tim Lohoff自2025年9月起担任BraveHeart Bio，Inc.董事会成员。目前，他是Forbion Ventures的负责人，这是一家投资于生物技术公司的全球风险投资公司，自2022年2月以来，他在该公司担任过各种职务。他还在几家私营生物技术公司担任董事会成员。在加入Forbion之前，他的职业生涯始于2021年8月至2022年2月在L.E.K. Consulting LLC担任生命科学专家。Lohoff博士于2021年获得了剑桥大学的博士学位，德累斯顿工业大学的硕士学位和比勒费尔德大学的学士学位。


Tim Lohoff has served as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Currently he is a Principal at Forbion Ventures, a global venture capital firm investing in biotech companies, where he has held various roles since February 2022. He also serves as a member of the board of directors at several private biotechnology companies. Prior to Forbion, he began his career as a Life Sciences Specialist at L.E.K. Consulting LLC from August 2021 to February 2022. Dr. Lohoff has received his Ph.D. from University of Cambridge in 2021, his M.Sc from TU Dresden and B.Sc from University of Bielefeld.
Tim Lohoff自2025年9月起担任BraveHeart Bio，Inc.董事会成员。目前，他是Forbion Ventures的负责人，这是一家投资于生物技术公司的全球风险投资公司，自2022年2月以来，他在该公司担任过各种职务。他还在几家私营生物技术公司担任董事会成员。在加入Forbion之前，他的职业生涯始于2021年8月至2022年2月在L.E.K. Consulting LLC担任生命科学专家。Lohoff博士于2021年获得了剑桥大学的博士学位，德累斯顿工业大学的硕士学位和比勒费尔德大学的学士学位。
Tim Lohoff has served as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Currently he is a Principal at Forbion Ventures, a global venture capital firm investing in biotech companies, where he has held various roles since February 2022. He also serves as a member of the board of directors at several private biotechnology companies. Prior to Forbion, he began his career as a Life Sciences Specialist at L.E.K. Consulting LLC from August 2021 to February 2022. Dr. Lohoff has received his Ph.D. from University of Cambridge in 2021, his M.Sc from TU Dresden and B.Sc from University of Bielefeld.
Jason Coloma

自2024年5月成立以来，Jason Coloma一直担任BraveHeart Bio，Inc.的董事会成员。目前，Coloma博士自2019年6月起担任Maze Therapeutics，Inc.（纳斯达克：MAZE）的总裁、首席执行官和董事会成员。在此之前，他是Third Rock Ventures，LLC的风险合伙人，2016年7月至2019年6月。在加入Third Rock之前，Coloma博士于2016年7月至2017年7月期间，在Corvus Pharmaceuticals, Inc.（纳斯达克：CRVS）担任高级副总裁兼首席商务官。在Third Rock任职期间，Coloma博士还曾于2018年8月至2019年8月在insitro，Inc.担任临时首席商务官，并于2017年7月至2018年11月在Celsius Therapeutics，Inc.（后被艾伯维公司（AbbVie Inc.，以下简称纳斯达克：ABBV））担任临时首席商务官。此前，他曾于2007年8月至2016年7月期间在罗氏集团和基因泰克（此前，NYSE：DNA）担任多个职务，包括副总裁兼全球治疗领域肿瘤学合作负责人以及研究技术合作全球负责人。他还于2002年6月至2005年7月在Cytokinetics公司（纳斯达克：CYTK）担任科学家，并曾在L.E.K. Consulting LLC和加州大学旧金山分校任职。Coloma博士此前曾于2021年4月至2024年8月在Bioage Labs，Inc.（纳斯达克：BIOA）担任董事会成员，目前在多家私营生物技术公司担任董事会成员。自2024年7月起，他还担任南加州大学和斯坦福大学的客座讲师。Coloma博士拥有旧金山大学生物学学士学位、加州大学伯克利分校博士和硕士学位，以及达特茅斯学院塔克商学院工商管理硕士学位。


Jason Coloma has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024. Currently, Dr. Coloma serves as President, Chief Executive Officer, and member of board of directors at Maze Therapeutics, Inc. (Nasdaq: MAZE) since June 2019. Prior to that, he was a venture partner at Third Rock Ventures, LLC, from July 2016 to June 2019. Before Third Rock, Dr. Coloma was SVP and Chief Business Officer at Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) from July 2016 to July 2017. While at Third Rock, Dr. Coloma also held the role of interim Chief Business Officer at insitro, Inc. from August 2018 to August 2019 and at Celsius Therapeutics, Inc. (later acquired by AbbVie Inc. (Nasdaq: ABBV)) from July 2017 to November 2018. Previously, he held several roles at Roche AG and Genentech, Inc. (previously, NYSE: DNA) between August 2007 and July 2016, including Vice President & Global Therapeutic Area Head of Oncology Partnering as well as Global Head of Research Technology Partnering. He also worked as a scientist at Cytokinetics Inc. (Nasdaq: CYTK) from June 2002 to July 2005 and held roles at L.E.K. Consulting LLC and University of California, San Francisco. Dr. Coloma previously served as a member of the board of directors at Bioage Labs, Inc. (Nasdaq: BIOA) from April 2021 to August 2024 and currently serves as a member of the board of directors at several private biotechnology companies. He is also a guest lecturer at University of Southern California and Stanford University since July 2024. Dr. Coloma holds a B.S. in Biology from the University of San Francisco, a Ph.D. and M.P.H. from the University of California, Berkeley, and an M.B.A. from the Tuck School of Business at Dartmouth College.
自2024年5月成立以来，Jason Coloma一直担任BraveHeart Bio，Inc.的董事会成员。目前，Coloma博士自2019年6月起担任Maze Therapeutics，Inc.（纳斯达克：MAZE）的总裁、首席执行官和董事会成员。在此之前，他是Third Rock Ventures，LLC的风险合伙人，2016年7月至2019年6月。在加入Third Rock之前，Coloma博士于2016年7月至2017年7月期间，在Corvus Pharmaceuticals, Inc.（纳斯达克：CRVS）担任高级副总裁兼首席商务官。在Third Rock任职期间，Coloma博士还曾于2018年8月至2019年8月在insitro，Inc.担任临时首席商务官，并于2017年7月至2018年11月在Celsius Therapeutics，Inc.（后被艾伯维公司（AbbVie Inc.，以下简称纳斯达克：ABBV））担任临时首席商务官。此前，他曾于2007年8月至2016年7月期间在罗氏集团和基因泰克（此前，NYSE：DNA）担任多个职务，包括副总裁兼全球治疗领域肿瘤学合作负责人以及研究技术合作全球负责人。他还于2002年6月至2005年7月在Cytokinetics公司（纳斯达克：CYTK）担任科学家，并曾在L.E.K. Consulting LLC和加州大学旧金山分校任职。Coloma博士此前曾于2021年4月至2024年8月在Bioage Labs，Inc.（纳斯达克：BIOA）担任董事会成员，目前在多家私营生物技术公司担任董事会成员。自2024年7月起，他还担任南加州大学和斯坦福大学的客座讲师。Coloma博士拥有旧金山大学生物学学士学位、加州大学伯克利分校博士和硕士学位，以及达特茅斯学院塔克商学院工商管理硕士学位。
Jason Coloma has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024. Currently, Dr. Coloma serves as President, Chief Executive Officer, and member of board of directors at Maze Therapeutics, Inc. (Nasdaq: MAZE) since June 2019. Prior to that, he was a venture partner at Third Rock Ventures, LLC, from July 2016 to June 2019. Before Third Rock, Dr. Coloma was SVP and Chief Business Officer at Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) from July 2016 to July 2017. While at Third Rock, Dr. Coloma also held the role of interim Chief Business Officer at insitro, Inc. from August 2018 to August 2019 and at Celsius Therapeutics, Inc. (later acquired by AbbVie Inc. (Nasdaq: ABBV)) from July 2017 to November 2018. Previously, he held several roles at Roche AG and Genentech, Inc. (previously, NYSE: DNA) between August 2007 and July 2016, including Vice President & Global Therapeutic Area Head of Oncology Partnering as well as Global Head of Research Technology Partnering. He also worked as a scientist at Cytokinetics Inc. (Nasdaq: CYTK) from June 2002 to July 2005 and held roles at L.E.K. Consulting LLC and University of California, San Francisco. Dr. Coloma previously served as a member of the board of directors at Bioage Labs, Inc. (Nasdaq: BIOA) from April 2021 to August 2024 and currently serves as a member of the board of directors at several private biotechnology companies. He is also a guest lecturer at University of Southern California and Stanford University since July 2024. Dr. Coloma holds a B.S. in Biology from the University of San Francisco, a Ph.D. and M.P.H. from the University of California, Berkeley, and an M.B.A. from the Tuck School of Business at Dartmouth College.
Christopher Viehbacher

Christopher Viehbacher，2008年12月1日，他被任命为首席执行官，还是战略委员会成员。Christopher Viehbacher是德国和加拿大公民。


Christopher Viehbacher has served as a member of Braveheart Bio, Inc.'s board of directors and Chairman of the board of directors since November 2025. Currently, Mr. Viehbacher is the President, Chief Executive Officer and a member of the board of directors of Biogen Inc. (Nasdaq: BIIB) since November 2022. Previously, Mr. Viehbacher was the co founder and managing partner at Gurnet Point Capital LLC, a Cambridge based healthcare investment fund from July 2015 to November 2022. Prior to that he was the Global Chief Executive Officer at Sanofi S.A. (Nasdaq: SNY) from December 2008 to October 2014 and started his career at GlaxoSmithKline plc (NYSE: GSK), where he held various roles between 1984 to 2008. Mr. Viehbacher previously served as the chair of the board of directors at PureTech Health plc (Nasdaq: PRTC) between March 2015 to May 2023 and has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology. He has received a number of awards including the Légion d'Honneur from France. He is Trustee of Northeastern University, a member of the Board of Fellows of the Stanford Medical School and a member of the MIT President's CEO Advisory Board. Mr. Viehbacher holds a B. Comm from Queen's University, Kingston, Canada. Viehbacher is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies.
Christopher Viehbacher，2008年12月1日，他被任命为首席执行官，还是战略委员会成员。Christopher Viehbacher是德国和加拿大公民。
Christopher Viehbacher has served as a member of Braveheart Bio, Inc.'s board of directors and Chairman of the board of directors since November 2025. Currently, Mr. Viehbacher is the President, Chief Executive Officer and a member of the board of directors of Biogen Inc. (Nasdaq: BIIB) since November 2022. Previously, Mr. Viehbacher was the co founder and managing partner at Gurnet Point Capital LLC, a Cambridge based healthcare investment fund from July 2015 to November 2022. Prior to that he was the Global Chief Executive Officer at Sanofi S.A. (Nasdaq: SNY) from December 2008 to October 2014 and started his career at GlaxoSmithKline plc (NYSE: GSK), where he held various roles between 1984 to 2008. Mr. Viehbacher previously served as the chair of the board of directors at PureTech Health plc (Nasdaq: PRTC) between March 2015 to May 2023 and has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology. He has received a number of awards including the Légion d'Honneur from France. He is Trustee of Northeastern University, a member of the Board of Fellows of the Stanford Medical School and a member of the MIT President's CEO Advisory Board. Mr. Viehbacher holds a B. Comm from Queen's University, Kingston, Canada. Viehbacher is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive international experience in both large pharmaceutical companies and entrepreneurial biotech companies.
David Malek

David Malek，2011年10月以来曾担任我们的业务发展副总裁。在加入公司之前，他从2006年到2011年在赛诺菲-安万特担任的管理职位，包括市场营销、财务和业务发展。最近，他担任肿瘤学主任——新产品和业务发展。他收到了达特茅斯大学塔克商学院的MBA学位和海法大学的统计数据和政治科学学士学位的。


David Malek has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024 and previously served as Braveheart Bio, Inc.'s President from May 2024 to October 2025. Currently, Mr. Malek is the Co Founder and Chief Operating Officer of an early development life sciences company since November 2024. Previously, he held various roles at Pivotal Life Sciences LLC, a life sciences venture capital firm investing in transformative therapeutic focused healthcare companies, from April 2018 to August 2025, including as Operating Partner, Investment Director and Venture Partner. Prior to that, Mr. Malek was the Chief Business Officer at OncXerna Therapeutics, Inc. from April 2017 to December 2021. Previously, he was the Chief Business Officer at Arctic Vision Ltd. from May 2019 to October 2020 and at BioLineRx Ltd. (Nasdaq: BLRX) from October 2011 to March 2018. He started his career at Sanofi S.A. (Nasdaq: SNY) where he held various roles from June 2007 to September 2011. Mr. Malek has also served as a member of the board of directors at several private biotechnology companies. He holds an B.A. from University of Haifa and an M.B.A. from the Tuck School of Business at Dartmouth College. Malek is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive experience and knowledge in the biotechnology sector.
David Malek，2011年10月以来曾担任我们的业务发展副总裁。在加入公司之前，他从2006年到2011年在赛诺菲-安万特担任的管理职位，包括市场营销、财务和业务发展。最近，他担任肿瘤学主任——新产品和业务发展。他收到了达特茅斯大学塔克商学院的MBA学位和海法大学的统计数据和政治科学学士学位的。
David Malek has served as a member of Braveheart Bio, Inc.'s board of directors since inception in May 2024 and previously served as Braveheart Bio, Inc.'s President from May 2024 to October 2025. Currently, Mr. Malek is the Co Founder and Chief Operating Officer of an early development life sciences company since November 2024. Previously, he held various roles at Pivotal Life Sciences LLC, a life sciences venture capital firm investing in transformative therapeutic focused healthcare companies, from April 2018 to August 2025, including as Operating Partner, Investment Director and Venture Partner. Prior to that, Mr. Malek was the Chief Business Officer at OncXerna Therapeutics, Inc. from April 2017 to December 2021. Previously, he was the Chief Business Officer at Arctic Vision Ltd. from May 2019 to October 2020 and at BioLineRx Ltd. (Nasdaq: BLRX) from October 2011 to March 2018. He started his career at Sanofi S.A. (Nasdaq: SNY) where he held various roles from June 2007 to September 2011. Mr. Malek has also served as a member of the board of directors at several private biotechnology companies. He holds an B.A. from University of Haifa and an M.B.A. from the Tuck School of Business at Dartmouth College. Malek is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive experience and knowledge in the biotechnology sector.

高管简历

中英对照 |  中文 |  英文
Travis Murdoch

Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。默多克博士自2022年8月起担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，从2020年9月至2022年10月，他在Zymergen，Inc.（现名：Ginkgo Bioworks Holdings Inc.（NYSE：DNA），在其合并后担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，默多克博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。由于拥有丰富的领导经验和生物制药行业知识，默多克有资格担任BraveHeart Bio，Inc.的董事会成员。


Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta. Murdoch is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive leadership experience and biopharmaceutical industry knowledge.
Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。默多克博士自2022年8月起担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，从2020年9月至2022年10月，他在Zymergen，Inc.（现名：Ginkgo Bioworks Holdings Inc.（NYSE：DNA），在其合并后担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，默多克博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。由于拥有丰富的领导经验和生物制药行业知识，默多克有资格担任BraveHeart Bio，Inc.的董事会成员。
Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta. Murdoch is qualified to serve on Braveheart Bio, Inc.'s board of directors due to his extensive leadership experience and biopharmaceutical industry knowledge.
Travis Murdoch

Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月期间担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。自2022年8月起，默多克博士担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，2020年9月至2022年10月，他在Zymergen，Inc.（合并后现名为Ginkgo Bioworks Holdings Inc.（NYSE：DNA））担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，Murdoch博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。


Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta.
Travis Murdoch自2025年7月起担任BraveHeart Bio，Inc.首席执行官，自2025年10月起担任BraveHeart Bio，Inc.总裁，自2025年9月起担任BraveHeart Bio，Inc.董事会成员。此前，默多克博士曾于2021年4月至2024年5月期间担任Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）的创始人、首席执行官兼董事，当时该公司被Biogen Inc.（纳斯达克：BIIB）收购。自2022年8月起，默多克博士担任Ollin Biosciences的董事和联合创始人，该公司是一家专注于眼部疾病的临床阶段生物技术公司。默多克博士此前还曾在2021年7月至2025年5月期间担任生命科学风险投资公司Monograph Capital Partners的联合创始人和合伙人。2020年2月至2023年1月，他在Karius，Inc.担任董事会成员，该公司是一家专注于传染病治疗的生物技术公司。在此之前，2020年9月至2022年10月，他在Zymergen，Inc.（合并后现名为Ginkgo Bioworks Holdings Inc.（NYSE：DNA））担任董事会成员。从2018年1月到2022年1月，默多克博士担任软银投资顾问公司的投资总监和顾问，专注于生命科学投资。从2019年到2022年1月，默多克博士在Guardant Health AMEA（纳斯达克：GH）担任董事会成员。他曾于2017年至2018年担任Third Rock Ventures的负责人，是Ambys Medicines和Rheos Medicines创始团队的一员。在此之前，Murdoch博士于2013年至2018年在艾伯塔省Health Sciences担任胃肠病学家和内科医生，并于2015年至2017年在麦肯锡公司担任顾问。默多克博士拥有牛津大学综合免疫学硕士学位，以及阿尔伯塔大学医学博士和医学学士学位。
Travis Murdoch has served as Braveheart Bio, Inc.'s Chief Executive Officer since July 2025, as Braveheart Bio, Inc.'s President since October 2025, and as a member of Braveheart Bio, Inc.'s board of directors since September 2025. Previously, Dr. Murdoch served as the Founder, Chief Executive Officer and Director at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from April 2021 to May 2024, when it was acquired by Biogen Inc. (Nasdaq: BIIB). Dr. Murdoch is a Director and co Founder at Ollin Biosciences, a clinical stage biotechnology company focused on eye diseases, since August 2022. Dr. Murdoch also previously served as a co Founder and Partner at Monograph Capital Partners, a life sciences venture capital firm from July 2021 to May 2025. From February 2020 to January 2023, he served as a board member at Karius, Inc., a biotechnology company focused on the treatment of infectious diseases. Prior to that, from September 2020 through October 2022, he served as a board member at Zymergen, Inc. (currently known as Ginkgo Bioworks Holdings Inc. (NYSE: DNA) following its merger). From January 2018 to January 2022, Dr. Murdoch was an Investment Director and Advisor with SoftBank Investment Advisors where he focused on life sciences investments. From 2019 to January 2022, Dr. Murdoch served as a board member at Guardant Health AMEA (Nasdaq: GH). He was previously a Principal at Third Rock Ventures from 2017 to 2018, where he was a part of the founding team at Ambys Medicines and Rheos Medicines. Prior to that Dr. Murdoch served as a gastroenterologist and internist at Alberta Health Sciences from 2013 to 2018, and a consultant at McKinsey & Company from 2015 to 2017. Dr. Murdoch holds an M.S. in integrated immunology from University of Oxford, as well as an M.D. and Bachelor of Medical Science from the University of Alberta.
J. Paul Rickey

J. Paul Rickey自2025年11月起担任BraveHeart Bio，Inc.的首席财务官。最近，Rickey先生通过2024年6月被福泰制药，Inc.（纳斯达克股票代码：纳斯达克：VRTX）收购，于2017年4月起在Alpine Immune Sciences, Inc.（前身为TERM1：ALPN）担任高级副总裁兼首席财务官，包括在2018年12月至2024年6月期间担任财务主管，并在2019年3月至2024年6月期间担任秘书。在此之前，Rickey先生于2016年3月至2017年3月在Sound Pharmaceuticals，Inc.担任首席财务官。在此之前，Rickey先生于2009年7月至2015年6月在Immune Design Corp.（前身为纳斯达克：IMDZ）担任副总裁、财务主管、秘书、首席财务官和首席会计官。在此之前，Rickey先生曾在公私生命科学和技术公司担任财务和运营职务，这些公司包括2006年7月至2009年6月期间的Northstar Neuroscience，Inc.（前身为纳斯达克：NSTR），以及2004年8月至2006年7月期间的Mobliss Inc.。他的职业生涯始于2001年至2004年的安永会计师事务所。Rickey先生拥有华盛顿大学专业会计学士和硕士学位，是一名注册会计师（非在职）。


J. Paul Rickey has served as Braveheart Bio, Inc.'s Chief Financial Officer since November 2025. Most recently, Mr. Rickey served as the SVP, Chief Financial Officer at Alpine Immune Sciences, Inc. (previously Nasdaq: ALPN) from April 2017 through its acquisition by Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX) in June 2024, including serving as its Treasurer from December 2018 to June 2024 and Secretary from March 2019 to June 2024. Prior to that, Mr. Rickey served as the Chief Financial Officer at Sound Pharmaceuticals, Inc. from March 2016 to March 2017. Prior to that, Mr. Rickey served as the Vice President, Treasurer, Secretary, Principal Financial Officer, and Principal Accounting Officer at Immune Design Corp. (previously, Nasdaq: IMDZ) from July 2009 to June 2015. Prior to that, Mr. Rickey held finance and operating roles at public and private life science and technology companies, including Northstar Neuroscience, Inc. (previously, Nasdaq: NSTR) from July 2006 to June 2009, and Mobliss Inc. from August 2004 to July 2006. He began his career at Ernst & Young from 2001 to 2004. Mr. Rickey holds a B.A. and Master of Professional Accounting from the University of Washington and is a Certified Public Accountant (inactive).
J. Paul Rickey自2025年11月起担任BraveHeart Bio，Inc.的首席财务官。最近，Rickey先生通过2024年6月被福泰制药，Inc.（纳斯达克股票代码：纳斯达克：VRTX）收购，于2017年4月起在Alpine Immune Sciences, Inc.（前身为TERM1：ALPN）担任高级副总裁兼首席财务官，包括在2018年12月至2024年6月期间担任财务主管，并在2019年3月至2024年6月期间担任秘书。在此之前，Rickey先生于2016年3月至2017年3月在Sound Pharmaceuticals，Inc.担任首席财务官。在此之前，Rickey先生于2009年7月至2015年6月在Immune Design Corp.（前身为纳斯达克：IMDZ）担任副总裁、财务主管、秘书、首席财务官和首席会计官。在此之前，Rickey先生曾在公私生命科学和技术公司担任财务和运营职务，这些公司包括2006年7月至2009年6月期间的Northstar Neuroscience，Inc.（前身为纳斯达克：NSTR），以及2004年8月至2006年7月期间的Mobliss Inc.。他的职业生涯始于2001年至2004年的安永会计师事务所。Rickey先生拥有华盛顿大学专业会计学士和硕士学位，是一名注册会计师（非在职）。
J. Paul Rickey has served as Braveheart Bio, Inc.'s Chief Financial Officer since November 2025. Most recently, Mr. Rickey served as the SVP, Chief Financial Officer at Alpine Immune Sciences, Inc. (previously Nasdaq: ALPN) from April 2017 through its acquisition by Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX) in June 2024, including serving as its Treasurer from December 2018 to June 2024 and Secretary from March 2019 to June 2024. Prior to that, Mr. Rickey served as the Chief Financial Officer at Sound Pharmaceuticals, Inc. from March 2016 to March 2017. Prior to that, Mr. Rickey served as the Vice President, Treasurer, Secretary, Principal Financial Officer, and Principal Accounting Officer at Immune Design Corp. (previously, Nasdaq: IMDZ) from July 2009 to June 2015. Prior to that, Mr. Rickey held finance and operating roles at public and private life science and technology companies, including Northstar Neuroscience, Inc. (previously, Nasdaq: NSTR) from July 2006 to June 2009, and Mobliss Inc. from August 2004 to July 2006. He began his career at Ernst & Young from 2001 to 2004. Mr. Rickey holds a B.A. and Master of Professional Accounting from the University of Washington and is a Certified Public Accountant (inactive).
Emil deGoma

Emil deGoma自2026年3月起担任BraveHeart Bio，Inc.的首席医疗官。最近，deGoma博士于2023年10月至2025年12月期间担任Tourmaline Bio，Inc.（前身，纳斯达克：TRML）的医学研究高级副总裁，包括在2025年10月完成对诺华公司的收购。此前，Dr. deGoma于2023年1月至2023年10月期间通过Radiem Consulting，LLC提供独立的临床开发咨询服务。在此之前，他曾于2021年11月至2022年10月在ChemoCentryx公司（原纳斯达克：CCXI）担任临床开发和数据科学高级副总裁，并在ChemoCentryx被收购后，于2022年10月至2022年12月担任安进，Inc.（纳斯达克：AMGN）临床开发副总裁。更早之前，他于2020年5月至2021年11月在Exicure, Inc.（纳斯达克：XCUR）担任临床开发副总裁。2019年8月至2020年4月，deGoma博士通过Radiem Consulting，LLC提供独立的临床开发咨询服务，并于2016年3月至2019年7月在Akebia Therapeutics, Inc.（纳斯达克：AKBA）担任职责不断增加的职位，最近担任临床开发副总裁。在其职业生涯的早期，德戈马博士曾担任宾夕法尼亚大学的助理教授和医学主任。德戈马博士获得了哈佛学院生化科学A.B.和哈佛医学院医学博士学位，并在斯坦福大学完成了内科住院医师和心血管医学研究金。德戈马博士是一名获得委员会认证的心脏病专家，是美国心脏病学会会员和美国心脏协会会员。


Emil deGoma has served as Braveheart Bio, Inc.'s Chief Medical Officer since March 2026. Most recently, Dr. deGoma served as Senior Vice President of Medical Research at Tourmaline Bio, Inc. (formerly, Nasdaq: TRML), from October 2023 to December 2025, including through the completion of its acquisition by Novartis AG in October 2025. Previously, Dr. deGoma provided independent clinical development consulting services through Radiem Consulting, LLC from January 2023 to October 2023. Before that, he served as Senior Vice President of Clinical Development & Data Science at ChemoCentryx, Inc. (formerly, Nasdaq: CCXI) from November 2021 to October 2022 and, following ChemoCentryx's acquisition, as Vice President of Clinical Development at Amgen, Inc. (Nasdaq: AMGN) from October 2022 to December 2022. Earlier, he served as Vice President of Clinical Development at Exicure, Inc. (Nasdaq: XCUR) from May 2020 to November 2021. From August 2019 to April 2020, Dr. deGoma provided independent clinical development consulting services through Radiem Consulting, LLC, and from March 2016 to July 2019, he served in positions of increasing responsibility at Akebia Therapeutics, Inc. (Nasdaq: AKBA), most recently as Vice President of Clinical Development. Earlier in his career, Dr. deGoma served as an Assistant Professor and Medical Director at the University of Pennsylvania. Dr. deGoma received an A.B. in Biochemical Sciences from Harvard College and an M.D. from Harvard Medical School and completed his internal medicine residency and cardiovascular medicine fellowship at Stanford University. Dr. deGoma is a board certified cardiologist and is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association.
Emil deGoma自2026年3月起担任BraveHeart Bio，Inc.的首席医疗官。最近，deGoma博士于2023年10月至2025年12月期间担任Tourmaline Bio，Inc.（前身，纳斯达克：TRML）的医学研究高级副总裁，包括在2025年10月完成对诺华公司的收购。此前，Dr. deGoma于2023年1月至2023年10月期间通过Radiem Consulting，LLC提供独立的临床开发咨询服务。在此之前，他曾于2021年11月至2022年10月在ChemoCentryx公司（原纳斯达克：CCXI）担任临床开发和数据科学高级副总裁，并在ChemoCentryx被收购后，于2022年10月至2022年12月担任安进，Inc.（纳斯达克：AMGN）临床开发副总裁。更早之前，他于2020年5月至2021年11月在Exicure, Inc.（纳斯达克：XCUR）担任临床开发副总裁。2019年8月至2020年4月，deGoma博士通过Radiem Consulting，LLC提供独立的临床开发咨询服务，并于2016年3月至2019年7月在Akebia Therapeutics, Inc.（纳斯达克：AKBA）担任职责不断增加的职位，最近担任临床开发副总裁。在其职业生涯的早期，德戈马博士曾担任宾夕法尼亚大学的助理教授和医学主任。德戈马博士获得了哈佛学院生化科学A.B.和哈佛医学院医学博士学位，并在斯坦福大学完成了内科住院医师和心血管医学研究金。德戈马博士是一名获得委员会认证的心脏病专家，是美国心脏病学会会员和美国心脏协会会员。
Emil deGoma has served as Braveheart Bio, Inc.'s Chief Medical Officer since March 2026. Most recently, Dr. deGoma served as Senior Vice President of Medical Research at Tourmaline Bio, Inc. (formerly, Nasdaq: TRML), from October 2023 to December 2025, including through the completion of its acquisition by Novartis AG in October 2025. Previously, Dr. deGoma provided independent clinical development consulting services through Radiem Consulting, LLC from January 2023 to October 2023. Before that, he served as Senior Vice President of Clinical Development & Data Science at ChemoCentryx, Inc. (formerly, Nasdaq: CCXI) from November 2021 to October 2022 and, following ChemoCentryx's acquisition, as Vice President of Clinical Development at Amgen, Inc. (Nasdaq: AMGN) from October 2022 to December 2022. Earlier, he served as Vice President of Clinical Development at Exicure, Inc. (Nasdaq: XCUR) from May 2020 to November 2021. From August 2019 to April 2020, Dr. deGoma provided independent clinical development consulting services through Radiem Consulting, LLC, and from March 2016 to July 2019, he served in positions of increasing responsibility at Akebia Therapeutics, Inc. (Nasdaq: AKBA), most recently as Vice President of Clinical Development. Earlier in his career, Dr. deGoma served as an Assistant Professor and Medical Director at the University of Pennsylvania. Dr. deGoma received an A.B. in Biochemical Sciences from Harvard College and an M.D. from Harvard Medical School and completed his internal medicine residency and cardiovascular medicine fellowship at Stanford University. Dr. deGoma is a board certified cardiologist and is a Fellow of the American College of Cardiology and a Fellow of the American Heart Association.
Michele Anderson

Michele Anderson自2025年10月起担任BraveHeart Bio，Inc.的首席开发官。最近，Anderson女士于2023年7月至2024年7月在Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）担任监管事务、药物警戒和质量高级副总裁，并在其被Biogen Inc.（纳斯达克：BIIB）收购后，于2024年7月至2025年10月担任渤健的West Coast Hub（前身为HI Bio）的监管事务、药物警戒和质量负责人，在那里她启动了felzartamab的第3阶段全球启动。在此之前，Anderson女士于2019年11月至2023年7月在Assembly Biosciences, Inc.（纳斯达克：ASMB）担任高级副总裁兼首席开发官。此前，Anderson女士曾于2009年3月至2019年11月在吉利德科学公司（纳斯达克：GILD）担任多个职务，领导HCV和HBV的抗病毒疗法的开发和全球批准所涉及的监管事务方面。2006年至2009年，Anderson女士担任CV Therapeutics Inc.（前身为纳斯达克：CVTX）监管事务高级经理。她的职业生涯于1998年至2006年在IMPAX Laboratories，Inc.（前身为纳斯达克：IPXL）开始。安德森女士拥有加州理工州立大学圣路易斯奥比斯波分校的生物科学学士学位。


Michele Anderson has served as Braveheart Bio, Inc.'s Chief Development Officer since October 2025. Most recently, Ms. Anderson served as the SVP, Regulatory Affairs, Pharmacovigilance, and Quality, at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from July 2023 to July 2024, and following its acquisition by Biogen Inc. (Nasdaq: BIIB), as Head of Regulatory Affairs, Pharmacovigilance, and Quality for Biogen's West Coast Hub (formerly HI Bio) from July 2024 to October 2025, where she launched the Phase 3 global start up for felzartamab. Prior to that, Ms. Anderson served as SVP and later Chief Development Officer at Assembly Biosciences, Inc. (Nasdaq: ASMB) from November 2019 to July 2023. Previously, Ms. Anderson held various roles at Gilead Sciences, Inc. (Nasdaq: GILD) from March 2009 to November 2019, where she led the regulatory affairs aspects involved in the development and worldwide approvals of antiviral therapies for HCV and HBV. From 2006 to 2009, Ms. Anderson was Senior Manager of Regulatory Affairs at CV Therapeutics Inc. (previously, Nasdaq: CVTX). She began her career at IMPAX Laboratories, Inc. (previously, Nasdaq: IPXL) from 1998 to 2006. Ms. Anderson holds a B.S. in Biological Sciences from California Polytechnic State University, San Luis Obispo.
Michele Anderson自2025年10月起担任BraveHeart Bio，Inc.的首席开发官。最近，Anderson女士于2023年7月至2024年7月在Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）担任监管事务、药物警戒和质量高级副总裁，并在其被Biogen Inc.（纳斯达克：BIIB）收购后，于2024年7月至2025年10月担任渤健的West Coast Hub（前身为HI Bio）的监管事务、药物警戒和质量负责人，在那里她启动了felzartamab的第3阶段全球启动。在此之前，Anderson女士于2019年11月至2023年7月在Assembly Biosciences, Inc.（纳斯达克：ASMB）担任高级副总裁兼首席开发官。此前，Anderson女士曾于2009年3月至2019年11月在吉利德科学公司（纳斯达克：GILD）担任多个职务，领导HCV和HBV的抗病毒疗法的开发和全球批准所涉及的监管事务方面。2006年至2009年，Anderson女士担任CV Therapeutics Inc.（前身为纳斯达克：CVTX）监管事务高级经理。她的职业生涯于1998年至2006年在IMPAX Laboratories，Inc.（前身为纳斯达克：IPXL）开始。安德森女士拥有加州理工州立大学圣路易斯奥比斯波分校的生物科学学士学位。
Michele Anderson has served as Braveheart Bio, Inc.'s Chief Development Officer since October 2025. Most recently, Ms. Anderson served as the SVP, Regulatory Affairs, Pharmacovigilance, and Quality, at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from July 2023 to July 2024, and following its acquisition by Biogen Inc. (Nasdaq: BIIB), as Head of Regulatory Affairs, Pharmacovigilance, and Quality for Biogen's West Coast Hub (formerly HI Bio) from July 2024 to October 2025, where she launched the Phase 3 global start up for felzartamab. Prior to that, Ms. Anderson served as SVP and later Chief Development Officer at Assembly Biosciences, Inc. (Nasdaq: ASMB) from November 2019 to July 2023. Previously, Ms. Anderson held various roles at Gilead Sciences, Inc. (Nasdaq: GILD) from March 2009 to November 2019, where she led the regulatory affairs aspects involved in the development and worldwide approvals of antiviral therapies for HCV and HBV. From 2006 to 2009, Ms. Anderson was Senior Manager of Regulatory Affairs at CV Therapeutics Inc. (previously, Nasdaq: CVTX). She began her career at IMPAX Laboratories, Inc. (previously, Nasdaq: IPXL) from 1998 to 2006. Ms. Anderson holds a B.S. in Biological Sciences from California Polytechnic State University, San Luis Obispo.
Marc Evanchik

Marc Evanchik自2026年1月起担任BraveHeart Bio，Inc.的首席科学官，此前曾于2025年10月至2026年1月担任BraveHeart Bio，Inc.的药理学和转化医学高级副总裁。最近，Evanchik先生于2020年12月至2025年2月在Edgewise Therapeutics, Inc.（纳斯达克：EWTX）担任发现和转化药理学副总裁，领导心血管研究。在此之前，Evanchik先生于2019年1月至2020年12月在Assembly Biosciences, Inc.（纳斯达克：ASMB）担任高级董事DMPK。此前，他曾于2012年10月至2018年9月在MyoKardia，Inc.（前身为纳斯达克：MYOK）担任多个职务，在建立药理学能力方面发挥了关键作用。2008年7月至2009年10月，Evanchik先生在ChemoCentryx，Inc.（前身为纳斯达克：CCXI）任职，2009年10月至2012年10月在3 V Biosciences，Inc.（现为Sagimet Biosciences，Inc.（丨纳斯达克纳斯达克：SGMT）任职。Evanchik先生的职业生涯始于2002年至2008年，担任Sunesis Pharmaceutics Inc.（现为Viracta Therapeutics, Inc.（纳斯达克：VIRX））的副科学家。Evanchik先生还是多项专利的发明人，这些专利涉及心肌疾病和心脏重塑的新疗法。他拥有加州大学圣克鲁斯分校化学学士学位和加州大学戴维斯分校化学硕士学位。


Marc Evanchik has served as Braveheart Bio, Inc.'s Chief Scientific Officer since January 2026 and was previously Braveheart Bio, Inc.'s SVP, Pharmacology and Translational Medicine from October 2025 to January 2026. Most recently, Mr. Evanchik was VP of Discovery and Translational Pharmacology at Edgewise Therapeutics, Inc. (Nasdaq: EWTX) from December 2020 to February 2025, where he led cardiovascular research. Prior to that, Mr. Evanchik served as the Senior Director DMPK at Assembly Biosciences, Inc. (Nasdaq: ASMB) from January 2019 to December 2020. Previously, he held various roles at MyoKardia, Inc. (previously, Nasdaq: MYOK) from October 2012 to September 2018 where he played a key role in establishing pharmacology capabilities. From July 2008 to October 2009, Mr. Evanchik was at ChemoCentryx, Inc. (previously, Nasdaq: CCXI) and from October 2009 to October 2012, he was at 3 V Biosciences, Inc. (currently, Sagimet Biosciences, Inc. (Nasdaq: SGMT)). Mr. Evanchik started his career as an Associate Scientist at Sunesis Pharmaceutics Inc. (currently, Viracta Therapeutics, Inc. (Nasdaq: VIRX)) from 2002 to 2008. Mr. Evanchik is also an inventor on multiple patents related to novel treatments for heart muscle disorders and cardiac remodeling. He holds a B.S. in Chemistry from the University of California, Santa Cruz, and an M.S. in Chemistry from the University of California, Davis.
Marc Evanchik自2026年1月起担任BraveHeart Bio，Inc.的首席科学官，此前曾于2025年10月至2026年1月担任BraveHeart Bio，Inc.的药理学和转化医学高级副总裁。最近，Evanchik先生于2020年12月至2025年2月在Edgewise Therapeutics, Inc.（纳斯达克：EWTX）担任发现和转化药理学副总裁，领导心血管研究。在此之前，Evanchik先生于2019年1月至2020年12月在Assembly Biosciences, Inc.（纳斯达克：ASMB）担任高级董事DMPK。此前，他曾于2012年10月至2018年9月在MyoKardia，Inc.（前身为纳斯达克：MYOK）担任多个职务，在建立药理学能力方面发挥了关键作用。2008年7月至2009年10月，Evanchik先生在ChemoCentryx，Inc.（前身为纳斯达克：CCXI）任职，2009年10月至2012年10月在3 V Biosciences，Inc.（现为Sagimet Biosciences，Inc.（丨纳斯达克纳斯达克：SGMT）任职。Evanchik先生的职业生涯始于2002年至2008年，担任Sunesis Pharmaceutics Inc.（现为Viracta Therapeutics, Inc.（纳斯达克：VIRX））的副科学家。Evanchik先生还是多项专利的发明人，这些专利涉及心肌疾病和心脏重塑的新疗法。他拥有加州大学圣克鲁斯分校化学学士学位和加州大学戴维斯分校化学硕士学位。
Marc Evanchik has served as Braveheart Bio, Inc.'s Chief Scientific Officer since January 2026 and was previously Braveheart Bio, Inc.'s SVP, Pharmacology and Translational Medicine from October 2025 to January 2026. Most recently, Mr. Evanchik was VP of Discovery and Translational Pharmacology at Edgewise Therapeutics, Inc. (Nasdaq: EWTX) from December 2020 to February 2025, where he led cardiovascular research. Prior to that, Mr. Evanchik served as the Senior Director DMPK at Assembly Biosciences, Inc. (Nasdaq: ASMB) from January 2019 to December 2020. Previously, he held various roles at MyoKardia, Inc. (previously, Nasdaq: MYOK) from October 2012 to September 2018 where he played a key role in establishing pharmacology capabilities. From July 2008 to October 2009, Mr. Evanchik was at ChemoCentryx, Inc. (previously, Nasdaq: CCXI) and from October 2009 to October 2012, he was at 3 V Biosciences, Inc. (currently, Sagimet Biosciences, Inc. (Nasdaq: SGMT)). Mr. Evanchik started his career as an Associate Scientist at Sunesis Pharmaceutics Inc. (currently, Viracta Therapeutics, Inc. (Nasdaq: VIRX)) from 2002 to 2008. Mr. Evanchik is also an inventor on multiple patents related to novel treatments for heart muscle disorders and cardiac remodeling. He holds a B.S. in Chemistry from the University of California, Santa Cruz, and an M.S. in Chemistry from the University of California, Davis.
Tyler Chavez

Tyler Chavez自2026年6月起担任BraveHeart Bio，Inc.的首席商务官。最近，Dr. Chavez在2025年8月至2026年6月期间担任Ouro Medicines LLC的企业发展主管，当时该公司被吉利德科学公司（纳斯达克：纳斯达克：LKFT）和Lakefront Biotherapeutics NV（泛欧交易所& TERM3：LKFT）收购。在此之前，他于2022年7月至2025年8月在Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）担任企业发展和联盟管理主管，包括在2024年7月被Biogen Inc.（纳斯达克：BIIB）收购后。此前，他曾于2019年12月至2022年7月在百济神州医药有限公司（纳斯达克：ONC）担任多个职务。Chavez博士曾于2018年11月至2019年12月在AppliedVR任职，于2017年5月至2018年11月在星火治疗公司（此前，纳斯达克：ONCE）任职，并于2014年10月至2017年4月在Johns Hopkins Technology Ventures任职，并在那里开始了他的职业生涯。Tyler拥有索诺玛州立大学化学学士学位、约翰霍普金斯大学有机化学硕士学位和约翰霍普金斯大学化学博士学位。


Tyler Chavez has served as Braveheart Bio, Inc.'s Chief Business Officer since June 2026. Most recently, Dr. Chavez was the Head of Corporate Development at Ouro Medicines LLC from August 2025 to June 2026, when it was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT). Prior to that, he served as Head of Corporate Development and Alliance Management at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from July 2022 to August 2025, including following its acquisition by Biogen Inc. (Nasdaq: BIIB) in July 2024. Previously, he held various roles at BeiGene Medicines Ltd. (Nasdaq: ONC) from December 2019 to July 2022. Dr. Chavez held prior roles at AppliedVR from November 2018 to December 2019, Spark Therapeutics, Inc. (previously, Nasdaq: ONCE) from May 2017 to November 2018 and at Johns Hopkins Technology Ventures from October 2014 to April 2017, where he started his career. Tyler holds a B.S. in Chemistry from Sonoma State University, an M.S. in Organic Chemistry from Johns Hopkins University and a Ph.D. in Chemistry from Johns Hopkins University.
Tyler Chavez自2026年6月起担任BraveHeart Bio，Inc.的首席商务官。最近，Dr. Chavez在2025年8月至2026年6月期间担任Ouro Medicines LLC的企业发展主管，当时该公司被吉利德科学公司（纳斯达克：纳斯达克：LKFT）和Lakefront Biotherapeutics NV（泛欧交易所& TERM3：LKFT）收购。在此之前，他于2022年7月至2025年8月在Human Immunology Biosciences，Inc.（f/k/a HI Bio，Inc.）担任企业发展和联盟管理主管，包括在2024年7月被Biogen Inc.（纳斯达克：BIIB）收购后。此前，他曾于2019年12月至2022年7月在百济神州医药有限公司（纳斯达克：ONC）担任多个职务。Chavez博士曾于2018年11月至2019年12月在AppliedVR任职，于2017年5月至2018年11月在星火治疗公司（此前，纳斯达克：ONCE）任职，并于2014年10月至2017年4月在Johns Hopkins Technology Ventures任职，并在那里开始了他的职业生涯。Tyler拥有索诺玛州立大学化学学士学位、约翰霍普金斯大学有机化学硕士学位和约翰霍普金斯大学化学博士学位。
Tyler Chavez has served as Braveheart Bio, Inc.'s Chief Business Officer since June 2026. Most recently, Dr. Chavez was the Head of Corporate Development at Ouro Medicines LLC from August 2025 to June 2026, when it was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT). Prior to that, he served as Head of Corporate Development and Alliance Management at Human Immunology Biosciences, Inc. (f/k/a HI Bio, Inc.) from July 2022 to August 2025, including following its acquisition by Biogen Inc. (Nasdaq: BIIB) in July 2024. Previously, he held various roles at BeiGene Medicines Ltd. (Nasdaq: ONC) from December 2019 to July 2022. Dr. Chavez held prior roles at AppliedVR from November 2018 to December 2019, Spark Therapeutics, Inc. (previously, Nasdaq: ONCE) from May 2017 to November 2018 and at Johns Hopkins Technology Ventures from October 2014 to April 2017, where he started his career. Tyler holds a B.S. in Chemistry from Sonoma State University, an M.S. in Organic Chemistry from Johns Hopkins University and a Ph.D. in Chemistry from Johns Hopkins University.